Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252142 | 0.90 | MMP13 (0.49) | MMP13TACR1ACKR3GPR119PDE4B | |
| SCHEMBL31412656 | 0.84 | MMP13 (0.52) | MMP13ACKR3GPR119PDE4BUSP30 | |
| SCHEMBL8244784 | 0.81 | TACR1 (0.47) | MMP13TACR1ACKR3GPR119PDE4B | |
| SCHEMBL953506 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL953505 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL2244835 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL14400171 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL2239870 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL2240156 | 0.80 | TACR1 (0.61) | TACR1GPR119PDE4BUSP30SLC6A4 | |
| SCHEMBL8245301 | 0.80 | TACR1 (0.52) | TACR1GPR119PDE4BUSP30JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | MMP13 415/4885TACR1 134/4885ACKR3 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.